List of Health2Sync Patient Management Platform Customers
Taipei, 114,
Taiwan
Since 2010, our global team of researchers has been studying Health2Sync Patient Management Platform customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Health2Sync Patient Management Platform for Patient Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Health2Sync Patient Management Platform for Patient Management include: AstraZeneca, a United Kingdom based Life Sciences organisation with 94300 employees and revenues of $73.98 billion, Sompo Holdings, a Japan based Insurance organisation with 80000 employees and revenues of $35.91 billion, Sanofi KK Japan, a Japan based Life Sciences organisation with 1341 employees and revenues of $1.43 billion, Novo Nordisk Japan, a Japan based Life Sciences organisation with 1068 employees and revenues of $83.3 million and many others.
Contact us if you need a completed and verified list of companies using Health2Sync Patient Management Platform, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Health2Sync Patient Management Platform customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
AstraZeneca | Life Sciences | 94300 | $74.0B | United Kingdom | Health2Sync | Health2Sync Patient Management Platform | Patient Management | 2022 | n/a |
In 2022, AstraZeneca Taiwan signed an MOU with Health2Sync to deploy the Health2Sync Patient Management Platform for early detection and digital management of chronic kidney disease across Taiwanese providers. The engagement positions AstraZeneca to use the Health2Sync Patient Management Platform within clinical care and chronic disease management programs, with explicit focus on screening and longitudinal patient monitoring under the Patient Management category.
The implementation centers on Health2Sync Patient Management Platform capabilities for chronic kidney disease, including inferred usage of CKD risk detection and patient monitoring features described in the announcement. The platform configuration emphasizes automated filtering and categorization of laboratory results to surface at-risk patients, combined with risk stratification and patient follow up workflows to enable earlier clinical intervention consistent with Patient Management functional patterns.
Operational coverage is scoped to Taiwanese provider networks with program governance led by AstraZeneca Taiwan and Health2Sync, targeting clinical care teams, nephrology services, and population health management functions. Integration work includes connecting laboratory result streams into the Health2Sync Patient Management Platform and routing flagged patients into monitoring workflows and clinical review queues for follow up.
Governance and rollout are organized through the MOU framework, aligning clinical protocols and data handling between AstraZeneca Taiwan and Health2Sync, and establishing clinical workflow touchpoints for provider adoption. The program explicitly frames the Health2Sync Patient Management Platform as a digital patient management layer for CKD early detection and ongoing monitoring within AstraZeneca Taiwan’s chronic disease management initiatives.
|
 |
Novo Nordisk Japan | Life Sciences | 1068 | $83M | Japan | Health2Sync | Health2Sync Patient Management Platform | Patient Management | 2019 | n/a |
In 2019, Novo Nordisk Japan implemented the Health2Sync Patient Management Platform in partnership with Health2Sync to support digital diabetes management in Japan. The Health2Sync Patient Management Platform is categorized as Patient Management and was localized and promoted by Novo Nordisk Pharma Ltd. following a December agreement announced in a March 5, 2019 press release from Taipei and Tokyo.
The implementation focused on the Health2Sync mobile App and companion web healthcare provider platform, delivering blood glucose trend analysis and treatment effectiveness tracking for clinicians and patients. The platform embeds a behavioral AI engine that provides contextual hints and nudges concerning meals, exercise, and blood glucose management, supporting patient engagement and adherence workflows common to Patient Management applications.
Operational coverage centered on enabling frequent digital touch points between people living with diabetes and their healthcare providers, bridging gaps between clinic visits. Deployment emphasized localized content and promotion for the Japanese market, with the platform used by doctors, patients, and Japanese healthcare providers to share data and insights through mobile and web channels.
Governance of the rollout was driven by the commercial partnership between Health2Sync and Novo Nordisk Pharma Ltd., aligning product localization, promotion, and provider outreach with Novo Nordisk’s patient centred business approach. The announced collaboration positioned the Health2Sync Patient Management Platform to deliver clinician facing trend visibility and patient facing engagement tools, and it was presented by both organizations as a capability to demonstrate shared value for the patient, the physician, and the Japanese healthcare provider.
|
 |
Sanofi KK Japan | Life Sciences | 1341 | $1.4B | Japan | Health2Sync | Health2Sync Patient Management Platform | Patient Management | 2022 | n/a |
In 2022, Sanofi KK Japan deployed the Health2Sync Patient Management Platform as a Patient Management application to deliver digitized insulin management support for patients and healthcare providers in Japan. The deployment reflects a partnering agreement with Health2Sync focused on clinical care and chronic disease management for insulin treated patients, and positions the Health2Sync Patient Management Platform as the operational hub for insulin titration workflows and patient monitoring.
The implementation centers on insulin titration and patient management capabilities, including use of connected caps for dose capture and titration alerts for patients and HCPs. Configuration work emphasized insulin titration logic, patient enrollment and remote monitoring workflows, and HCP-facing management screens to review dosing history and alert triage, consistent with Patient Management functional workflows.
Operational coverage is Japan, serving patients and healthcare professionals in clinical settings and outpatient diabetes care. Governance was established through the Sanofi and Health2Sync partnering agreement, aligning clinical protocols and titration thresholds with platform configuration and rollout decisions. The program explicitly targets improved insulin titration and glycemic control as primary clinical objectives.
|
 |
|
Insurance | 80000 | $35.9B | Japan | Health2Sync | Health2Sync Patient Management Platform | Patient Management | 2022 | n/a |
|
Buyer Intent: Companies Evaluating Health2Sync Patient Management Platform
- Korman Residential, a United States based Construction and Real Estate organization with 80 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||